Abstract
This Phase II study evaluated analgesia, abuse liability, and cognitive performance of hydromorphone and oral delta-9-tetrahydrocannabinol (THC; dronabinol) using a within-subject, double-blind, randomized, placebo-controlled, human laboratory trial. Healthy adults (N = 29) with no history of drug use disorder received combinations of placebo, hydromorphone (4 mg; oral), and dronabinol (2.5 mg, 5.0 mg, 10 mg; oral). Primary outcomes were quantitative sensory testing (QST) measures of acute (thermal, pressure pain; thermal, punctate probe temporal summation; cold pressor; conditioned pain modulation) and chronic pain (capsaicin 10% topical cream with thermal rekindling), measures of drug abuse liability, cognitive functioning, and adverse events. Subgroup analyses were conducted within opioid-responders (endorsed >20 on a Drug Effect visual analog scale during the hydromorphone-only condition) and nonresponders. A consistent dose-effect relationship of dronabinol on hydromorphone across all measures was not observed. Analgesia only improved in the hydromorphone + dronabinol 2.5 mg condition. Hydromorphone + dronabinol 2.5 mg showed the lowest and hydromorphone+dronabinol 5 mg showed the highest risk for abuse. Hydromorphone+dronabinol 10 mg produced a high rate of dysphoric effects, and hydromorphone+dronabinol 5 mg and hydromorphone + dronabinol 10 mg produced AEs. Subgroup analyses showed subjective effects and abuse risk was increased among opioid responders and largely absent among nonresponders. Overall, only hydromorphone+dronabinol 2.5 mg modestly enhanced hydromorphone-based analgesia and hydromorphone + dronabinol 5 mg and 10 mg increased risk for abuse and AEs. These data can help inform opioid-sparing efforts in clinical pain populations. Demonstration that potential opioid effects varied as a function of participant opioid sensitivity (e.g., responder status) is a novel finding that warrants additional research.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Ciccarone D. The triple wave epidemic: supply and demand drivers of the US opioid overdose crisis. Int J Drug Policy. 2019;71:183–8.
Dowell D, Arias E, Kochanek K, et al. Contribution of opioid-involved poisoning to the change in life expectancy in the United States, 2000–2015. JAMA. 2017;318:1065–7.
Shah A, Hayes CJ, Martin BC. Characteristics of initial prescription episodes and likelihood of long-term opioid use—United States, 2006–2015. Morb Mortal Wkly Rep. 2017;66:265–9.
Zhang Y, Johnson P, Jeng PJ, Reid MC, Witkin LR, Schackman BR, et al. First opioid prescription and subsequent high-risk opioid use: a national study of privately insured and Medicare advantage adults. J Gen Intern Med. 2018;33:2156–62.
Raman SR, Bush C, Karmali RN, Greenblatt LH, Roberts AW, Skinner AC. Characteristics of new opioid use among medicare beneficiaries: identifying high-risk patterns. J Managed Care Specialty Pharm. 2019;25:966–72.
LaPietra AM, Motov S. A country in crisis: opioid sparing solutions for acute pain management. Mol Med. 2019;116:140.
Foll L. Opioid-sparing effects of cannabinoids: myth or reality? Prog Neuro-Psychopharmacol Biol Psychiatry. 2020:110065.
Babalonis S, Walsh SL. Therapeutic potential of opioid/cannabinoid combinations in humans: review of the evidence. Eur Neuropsychopharmacol. 2020.
Nielsen S, Sabioni P, Trigo JM, Ware MA, Betz-Stablein BD, Murnion B, et al. Opioid-sparing effect of cannabinoids: a systematic review and meta-analysis. Neuropsychopharmacology. 2017;42:1752–65.
Birch EA. The use of Indian hemp in the treatment of chronic chloral and chronic opium poisoning. Lancet. 1889;1:25.
Maguire DR, Yang W, France CP. Interactions between mu-opioid receptor agonists and cannabinoid receptor agonists in rhesus monkeys: antinociception, drug discrimination, and drug self-administration. J Pharm Exp Ther. 2013;345:354–62.
Dunn KE, Huhn AS, Bergeria CL, Gipson CD, Weerts EM. Non-opioid neurotransmitter systems that contribute to the opioid withdrawal syndrome: a review of preclinical and human evidence. J Pharm Exp Ther. 2019;371:422–52.
Corroon JM Jr, Mischley LK, Sexton M. Cannabis as a substitute for prescription drugs–a cross-sectional study. J Pain Res. 2017;10:989–98.
Lucas P, Walsh Z, Crosby K, Callaway R, Belle-Sile L, Kay R, et al. Substituting cannabis for prescription drugs, alcohol and other substances among medical cannabis patients: The impact of contextual factors. Drug Alcohol Rev. 2016;35:326–33.
Bergeria CL, Huhn AS, Dunn KE. The impact of naturalistic cannabis use on self-reported opioid withdrawal. J Subst Abuse Treat. 2020:108005.
Lötsch J, Weyer‐Menkhoff I, Tegeder I. Current evidence of cannabinoid‐based analgesia obtained in preclinical and human experimental settings. Eur J Pain. 2018;22:471–84.
Bachhuber MA, Saloner B, Cunningham CO, Barry CL. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. JAMA Intern Med. 2014;174:1668–73.
Campbell G, Hall W, Nielsen S. What does the ecological and epidemiological evidence indicate about the potential for cannabinoids to reduce opioid use and harms? A comprehensive review. Int Rev Psychiatry. 2018;30:91–106.
Humphreys K, Saitz R. Should physicians recommend replacing opioids with cannabis? JAMA. 2019;321:639–40.
Hindley G, Beck K, Borgan F, Ginestat CE, McCutcheon R, Kleinloog D, et al. Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis. Lancet Psychiatry. 2020.
Hobbs M, Kalk NJ, Morrison PD, Stone JM. Spicing it up-synthetic cannabinoid receptor agonists and psychosis-a systematic review. Eur Neuropsychopharmacol. 2018;28:1289–304.
Shover CL, Davis CS, Gordon SC, Humphreys K. Association between medical cannabis laws and opioid overdose mortality has reversed over time. Proc Natl Acad Sci. 2019;116:12624–6.
Naef M, Curatolo M, Petersen-Felix S, Arendt-Nielsen L, Zbinden A, Brenneisen R. The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain. 2003;105:79–88.
Roberts JD, Gennings C, Shih M. Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. Eur J Pharmacol. 2006;530:54–8.
Babalonis S, Lofwall MR, Sloan PA, Nuzzo PA, Fanucchi LC, Walsh SL. Cannabinoid modulation of opioid analgesia and subjective drug effects in healthy humans. Psychopharmacology. 2019;236:3341–52.
Cooper ZD, Bedi G, Ramesh D, Balter R, Comer SD, Haney M. Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability. Neuropsychopharmacology. 2018;43:2046–55.
Aviram J, Samuelly-Leichtag G. Efficacy of cannabis-based medicines for pain management: a systematic review and meta-analysis of randomized controlled trials. Pain Physician. 2017;20:E755–E96.
Comer SD, Zacny JP, Dworkin RH, Turk DC, Bigelow GE, Foltin RW, et al. Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations. Pain. 2012;153:2315–24.
Overholser BR, Foster DR. Opioid pharmacokinetic drug-drug interactions. Am J Manag Care. 2011;17:S276–S87.
Dunn KE, Brands B, Marsh DC, Bigelow GE. Characterizing the subjective, observer-rated, and physiological effects of hydromorphone relative to heroin in a human laboratory study. Psychopharmacology. 2018;235:971–81.
Dunn KE, Barrett FS, Brands B, Marsh DC, Bigelow GE. Individual differences in human opioid abuse potential as observed in a human laboratory study. Drug Alcohol Depend. 2019;205:107688.
Carter LP, Griffiths RR. Principles of laboratory assessment of drug abuse liability and implications for clinical development. Drug Alcohol Depend. 2009;105:14.
Arendt-Nielsen L. Central sensitization in humans: assessment and pharmacology. Handb Exp Pharmacol. 2015;227:79–102.
Campbell CM, Buenaver LF, Raja SN, Kiley KB, Swedberg LJ, Wacnik PW, et al. Dynamic pain phenotypes are associated with spinal cord stimulation-induced reduction in pain: a repeated measures observational pilot study. Pain Med. 2015;16:1349–60.
Rolke R, Baron R, Maier CA, Tolle TR, Treede DR, Beyer A, et al. Quantitative sensory testing in the German research network on neuropathic pain (DFNS): standardized protocol and reference values. Pain. 2006;123:231–43.
Campbell CM, Buenaver LF, Finan P, Bounds SC, Redding M, McCauley L, et al. Sleep, pain catastrophizing, and central sensitization in knee osteoarthritis patients with and without insomnia. Arthritis Care Res. 2015;67:1387–96.
Dirks J, Petersen KL. The heat/capsaicin sensitization model: a methodologic study. J Pain. 2003;4:122–8.
Mathiesen O, Imbimbo BP, Hilsted KL, Fabbri L, Dahl JB. CHF3381, a N-methyl-D-aspartate receptor antagonist and monoamine oxidase—a inhibitor, attenuates secondary hyperalgesia in a human pain model. J Pain. 2006;7:565–74.
Treede R, Meyer RA, Raja SN, Campbell JN. Peripheral and central mechanisms of cutaneous hyperalgesia. Prog Neurobiol. 1992;38:397–421.
Frymoyer AR, Rowbotham MC, Petersen KL. Placebo-controlled comparison of a morphine/dextromethorphan combination with morphine on experimental pain and hyperalgesia in healthy volunteers. J Pain. 2007;8:19–25.
Petersen KL, Rowbotham MC. A new human experimental pain model: the heat/capsaicin sensitization model. Neuroreport. 1999;10:1511–6.
US Food and Drug Administration. Assessment of abuse potential of drugs: Guidance for industry. US Department of Health and Human Services. https://www.fda.gov/downloads/drugs/guidances/ucm198650.pdf. 2017. Accessed 04 April 2021.
Herrmann ES, Cone EJ, Mitchell JM, Bigelow GE, LoDico C, Flegel R, et al. Non-smoker exposure to secondhand cannabis smoke II: effect of room ventilation on the physiological, subjective, and behavioral/cognitive effects. Drug Alcohol Depend. 2015;151:194–202.
Mintzer MZ. Effects of opioid pharmacotherapy on psychomotor and cognitive performance: a review of human laboratory studies of methadone and buprenorphine. Heroin Addiction Relat Clin Probl. 2007;9:5–24.
Mintzer MZ, Copersino ML, Stitzer ML. Opioid abuse and cognitive performance. Drug Alcohol Depend. 2005;78:225–30.
Antoine DG, Strain EC, Tompkins DA, Bigelow GE. Opioid abusers’ ability to differentiate an opioid from placebo in laboratory challenge testing. Drug Alcohol Depend. 2013;132:369–72.
O’Neill S, O’Neill L. Improving QST reliability—more raters, tests, or occasions? A multivariate generalizability study. J Pain. 2015;16:454–62.
Kennedy DL, Kemp HI, Ridout D, Yarnitsky D, Rice AS. Reliability of conditioned pain modulation: a systematic review. Pain. 2016;157:2410.
Nothnagel H, Puta C, Lehmann T, Baumbach P, Menard MB, Gabriel B, et al. How stable are quantitative sensory testing measurements over time? report on 10-week reliability and agreement of results in healthy volunteers. J Pain Res. 2017;10:2067–78.
Althouse AD. Adjust for multiple comparisons? it’s not that simple. Ann Thorac Surg. 2016;101:1644–45.
Acknowledgements
The study team thanks Ian Geithner, Megan Greene, Caitlyn Grubb, Jasmyne Jardot, Haley Puddy, Sandra Okobi, Leticia Nanda, and Dr. Annie Umbricht for their assistance with study sessions and Paul Nuzzo for his assistance conducting data analyses.
Author information
Authors and Affiliations
Contributions
KED, RV, and CMC designed the trial and received grant funding, all study authors contributed to daily management of the study and session completion, KED led the data analyses and drafted the first edition of the manuscript, all authors reviewed and contributed to the final study manuscript.
Corresponding author
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Dunn, K.E., Bergeria, C.L., Huhn, A.S. et al. Within-subject, double-blinded, randomized, and placebo-controlled evaluation of the combined effects of the cannabinoid dronabinol and the opioid hydromorphone in a human laboratory pain model. Neuropsychopharmacol. 46, 1451–1459 (2021). https://doi.org/10.1038/s41386-021-01007-4
Received:
Revised:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41386-021-01007-4
This article is cited by
-
“Medical Cannabis”: Advising Patients While Navigating Medical Ethics and Limited Evidence
Journal of General Internal Medicine (2025)
-
Medicine vs. Myth: Exploring the Therapeutic Potential of Cannabis for Opioid Use Disorder and Pain
Current Addiction Reports (2025)
-
Does cannabis use substitute for opioids? A preliminary exploratory survey in opioid maintenance patients
European Archives of Psychiatry and Clinical Neuroscience (2025)
-
The State of Synthetic Cannabinoid Medications for the Treatment of Pain
CNS Drugs (2024)
-
Oral Delta-9-Tetrahydrocannabinol (THC) Increases Parasympathetic Activity and Supraspinal Conditioned Pain Modulation in Chronic Neuropathic Pain Male Patients: A Crossover, Double-Blind, Placebo-Controlled Trial
CNS Drugs (2024)
